美第奇新星生物技术 MNOV 深 沪
等待开盘 10-27 09:30:00 美东时间
1.4101
+0.020
+1.45%
华盛通- 最 高1.47
- 今 开1.42
- 成交量 7.60万股
- 最 低 1.40
- 昨 收 1.39
- 总市值 6940.69万
- 52周最高 3.8999
- 市盈率 静 --
- 换手率 0.15%
- 52周最低 1.22
- 委 比 6.70%
- 总股本 4922.12万
- 历史最高 14.50
- 量 比 2.00
- 振 幅 5.04%
- 历史最低 1.12
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美第奇新星生物技术收涨3.68%，成交额4.54万美元
10月22日，美第奇新星生物技术（MNOV）收涨3.68%，报1.41美元，成交额4.54万美元，市值6940.17万美元。 行情数据 • 开盘价：1.37美元...
10-22 07:19
美第奇新星生物技术收跌2.07%，成交额11.55万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:18
MediciNova CEO Provides Shareholder Update
MediciNova, Inc. provided an update on its Phase 2 clinical trial evaluating MN-001 (tipelukast) for nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia associated with type 2 diabetes mellitus. While the trial did not achieve statistical significance on its primary endpoints, encouraging signals were observed, including improvements in HDL-C, HDL-P, and early reduction in triglycerides. MN-001 was well-tolerated with no serious adv...
10-12 10:00
MediciNova to Participate in the Maxim Growth Summit
MediciNova, a clinical-stage biopharmaceutical company, announced that its management will participate in the Maxim Growth Summit on October 12-14, 2026, in New York. Investors can schedule one-on-one meetings with MediciNova's management through their Maxim representative or via a provided link. The company specializes in developing small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases, with its lead asset MN-166 (i...
10-06 10:00
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 demonstrated statistically significant increases in HDL-C and HDL-P, significant early reduction in triglycerides, and numerical improvements in liver fat and body weight in a Phase 2 clinical trial for hypertriglyceridemia and NAFLD associated with T2DM. The study showed favorable safety and tolerability, with no serious adverse events. These findings suggest potential beneficial effects on lipid metabolism, body weight, and liver fat, su...
09-28 10:00
MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis
A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label Extension phase. The LPLV for the entire study is expected in March 2027. MediciNova...
09-24 18:10
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $6.
09-17 17:52
MediciNova to Participate in Two Investor Conferences in September
<p>MediciNova, Inc. announced that its President and CEO, Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer, David H. Crean, Ph.D., will participate in two investor conferences in September. They will attend the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16 and the ROTH Capital 5th Annual Healthcare Opportunities Conference on September 29. Both events will feature virtual presentations and investor meetings. The...
09-08 10:00
